Combined Modality Molecular Targeted Therapy, Head/Neck Squamous Cell Carcinoma: Multimedia

References

1. Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res. Oct 1 2003;9(12):4287-95. [Medline].

2. Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. Jun 18 1999;274(25):17612-8. [Medline].

3. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. Sep 2001;37 Suppl 4:S3-8. [Medline].

4. Wells A. EGF receptor. Int J Biochem Cell Biol. Jun 1999;31(6):637-43. [Medline].

5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. Feb 2001;2(2):127-37. [Medline].

6. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. Jul 3 2000;19(13):3159-67. [Medline].

7. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. May-Jun 1999;82(2-3):241-50. [Medline].

8. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol. Feb 2003;30(1 Suppl 1):3-11. [Medline].

9. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. Sep 15 2001;19(18 Suppl):32S-40S. [Medline].

10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. Jan 9 1987;235(4785):177-82. [Medline].

11. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. Feb 1 2002;20(3):719-26. [Medline].

12. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. Feb 2001;28(1 Suppl 3):13-9. [Medline].

13. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. Apr 10 2005;23(11):2534-43. [Medline].

14. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. Nov 1 2000;18(21 Suppl):47S-53S. [Medline].

15. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. Jul 1 2001;19(13):3234-43. [Medline].

16. Kies MS, Arquette M, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody, cetuximab (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SSCHN) refractory to cisplatin containing c. Proc Am Soc Clin Oncol. 2002;21:232a.

17. Baselga J, Trigo JM, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol. 2002;21:226a.

18. Burtness BA, Li Y, Flood W, et al. Phase III trial comparing cisplatin (C) + placebo (PP to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc Am Soc Clin Oncol. 2002;21:226a.

19. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) pluc irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol. 2001;21:2a.

20. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. Apr 27 1999;96(9):4995-5000. [Medline].

21. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. Feb 13 2003;421(6924):756-60. [Medline].

22. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. Oct 13 2000;103(2):211-25. [Medline].

23. Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol. 2002;21:21a.

24. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. Nov 2002;8(11):3496-502. [Medline].

25. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. Nov 1999;291(2):739-48. [Medline].

26. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. Oct 15 2002;62(20):5749-54. [Medline].

27. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. Jul 1 2001;19(13):3267-79. [Medline].

28. Senzer NN, Soulieres D, Siu L, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2001;20:2a.

29. Hidalgo M. Phase I studies/combination therapy with Tarceva (erlotinib HCL;OSI-774) in head and neck cancer. Presented at: The First Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck cancer. San Juan, Puerto Rico:. February 5-9, 2003.

30. Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. Dec 2001;7(12):4230-8. [Medline].

31. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. Aug 20 2005;23(24):5578-87. [Medline].

32. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. Aug 20 2005;23(24):5568-77. [Medline].

33. Vermorken JB, Mesia R, Vega-Villegas ME, et al. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2006;24:289s. Abstract 5537.

34. Kies MS, Garden AS, Holsinger C, et al. Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2006;24:285s. Abstract 5520.

35. Savvides P, Agarwala SS, Greskovich J, et al. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol. 2006;24:291s. Abstract 5545.

36. Kim ES, Kies MS, Glisson BS, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:285s. Abstract 5521.

37. Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol. 2006;24:290s. Abstract 5543.

38. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. Apr 15 2005;65(8):3003-10. [Medline].

39. Harrington KJ, Bourhis J, Nutting CM, et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2006;24:293s. Abstract 5553.

40. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2006;24:297s. Abstract 5568.

41. Vokes EE, Cohen EEW, Mauer AM, et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol. 2005;23:5504.

42. Seiwert TY, Haraf DJ, Cohen EE, et al. A phase I study of bevacizumab with fluorouracil and hydroxyurea with concomitant radiotherapy for poor prognosis head and neck cancer. Proc Am Soc Clin Oncol. 2006;24:287s. Abstract 5530.

43. Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. Sep 2005;129(3):863-73. [Medline].

44. Prellop P, Peters G, Carroll W, Nabell L, Spencer S, Ove R. Radiosensitization with a COX2 inhibitor with chemoradiation for head and neck cancer. Proc Am Soc Clin Oncol. 2006;24:300s. Abstract 5582.

45. Kawakami K, Kawakami M, Puri RK. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol. Dec 15 2002;169(12):7119-26. [Medline].

46. Kawakami K, Husain SR, Kawakami M, Puri RK. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med. Aug 2002;8(8):487-94. [Medline].

47. Kawakami M, Kawakami K, Puri RK. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Int J Cancer. Jan 1 2003;103(1):45-52. [Medline].

48. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. Aug 2002;24(8):792-9. [Medline].

49. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab. Jun 2002;87(6):2525-31. [Medline].

50. Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res. Sep 1 2002;62(17):5049-57. [Medline].

51. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology. 2001;61 Suppl 2:14-21. [Medline].

52. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol. Jan 1998;184(1):53-7. [Medline].

53. Feng L, Wang Z. Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope. Oct 2006;116(10):1842-5. [Medline].

54. Feng L, Wang Z. Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope. Oct 2006;116(10):1842-5. [Medline].

55. Giordano A, Rustum YM, Wenner CE. Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem. Jul 1 1998;70(1):1-7. [Medline].

56. Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res. Aug 1 2003;9(8):3183-9. [Medline].

57. Liao CT, Tung-Chieh Chang J, Wang HM, Chen IH, Lin CY, Chen TM, et al. Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. Head Neck. Jun 2004;26(6):504-12. [Medline].

58. Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol. Sep 1 2005;70(5):658-67. [Medline].

59. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. Oct 1996;74(8):1253-7. [Medline].

60. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. Oct 1 2001;61(19):7184-8. [Medline].

61. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. Dec 15 2001;61(24):8887-95. [Medline].

62. Myers JN, Holsinger FC, Bekele BN, Li E, Jasser SA, Killion JJ, et al. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch Otolaryngol Head Neck Surg. Aug 2002;128(8):875-9. [Medline].

63. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. Mar 2001;8(1):11-31. [Medline].

64. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. Jun 3 1998;90(11):824-32. [Medline].

65. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res. 2000;78:31-101. [Medline].

66. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. Sep 2001;8(3):161-73. [Medline].

Further Reading

Keywords

squamous cell carcinoma of the head and neck, neck cancer, head cancer, neck malignancy, head malignancy, HNSCC, epidermal growth factor receptor, EGFR, human epidermal growth factor receptor, EGF, HER, HER1, HER2, HER2/neu, Her-1, Her-2, Her-2/neu, molecular medicine, molecular therapy, trastuzumab, STI-571, ERBB2, EGFR overexpression, EGFR tyrosine kinase, EGFR inhibitors, non–small-cell lung cancer, NSCLC, anticancer therapy, antitumor therapy, Pertuzumab 2C4, cetuximab, erlotinib, gefitinib, angiogenesis, interleukin-13 receptors, IL-13R, gene therapy, cyclooxygenase-2, COX-2 inhibitors, chemoprevention, carcinoembryonic antigen, CEA

Contributor Information and Disclosures

Author

Pankaj Chaturvedi, MBBS, MS, Associate Professor, Head and Neck Surgery, Department of Surgical Oncology, Tata Memorial Hospital, India
Pankaj Chaturvedi, MBBS, MS is a member of the following medical societies: American Association for the Advancement of Science and Association of Surgeons of India
Disclosure: Nothing to disclose.

Coauthor(s)

Bhavin Chandrakant Shah, MD, MS, MRCS, MIS, Advanced Laparoscopic Research Fellow, Department of Surgery, University of Nebraska Medical Center
Bhavin Chandrakant Shah, MD, MS, MRCS, MIS is a member of the following medical societies: Royal College of Surgeons of Edinburgh
Disclosure: Nothing to disclose.

Medical Editor

Benoit J Gosselin, MD, FRCSC, Associate Professor of Surgery, Dartmouth Medical School; Director, Comprehensive Head and Neck Oncology Program, Norris Cotton Cancer Center; Staff Otolaryngologist, Division of Otolaryngology-Head and Neck Surgery, Dartmouth-Hitchcock Medical Center
Benoit J Gosselin, MD, FRCSC is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Medical Association, American Rhinologic Society, Canadian Medical Association, Canadian Society of Otolaryngology-Head & Neck Surgery, College of Physicians and Surgeons of Ontario, New Hampshire Medical Society, North American Skull Base Society, and Ontario Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Karen Hall Calhoun, MD, Professor, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University
Karen Hall Calhoun, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Rhinologic Society, Association for Research in Otolaryngology, Society of University Otolaryngologists-Head and Neck Surgeons, Southern Medical Association, Texas Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown